Paclitaxel Accord

Paclitaxel, the active ingredient in Paclitaxel Accord, is a chemotherapy agent presented as a sterile injectable solution for intravenous use. It is used in the treatment of various solid tumours and haematologic malignancies in adult patients. GNH USA supplies Paclitaxel Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH USA supplies Paclitaxel Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Paclitaxel is employed in oncology to interfere ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​

- Breast cancer: improves disease‑free survival when combined with other agents. - Non‑small cell lung cancer: used as a first‑line or second‑line therapy in combination regimens. - Ovarian cancer: administered after surgical debulking to reduce recurrence risk. - Kaposi's sarcoma: provides antitumour activity in HIV‑related disease. - Gastric cancer: part of combination protocols for advanced disease. - Pancreatic cancer: used in multi‑drug regimens for metastatic disease.

Paclitaxel may elicit a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Alopecia: hair loss that may be temporary. - Peripheral neuropathy: tingling or numbness in extremities. - Nausea and vomiting: gastrointestinal upset. - Fatigue: generalised tiredness. - Myalgia: muscle aches.

Serious or Rare Side Effects: - Anaphylactic reactions: severe hypersensitivity requiring immediate medical attention. - Cardiotoxicity: arrhythmias or decreased cardiac function. - Severe neutropenic infection: febrile neutropenia. - Pulmonary toxicity: interstitial pneumonitis. - Hepatotoxicity: elevated liver enzymes or liver injury. - Thromboembolic events: deep vein thrombosis or pulmonary embolism.

When administering  ​  ​  ​   ​  ​  ​  ​  ​  ​  ​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​

- Assess  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​ - Monitor ​ ​  ... (the rest of the content has been truncated)

The   ​  ...